New Element Medicine

Zhenjiang, China Founded: 2012 • Age: 14 yrs
Drugs for cancer and metabolic diseases are developed.
Request Access

About New Element Medicine

New Element Medicine is a company based in Zhenjiang (China) founded in 2012 by Shi Dongfang.. New Element Medicine has raised $152.05 million across 5 funding rounds from investors including Livzon Pharmaceutical, Kaitai Capital and Fortune Capital Partners. New Element Medicine offers products and services including ABP-671 and ABP-745. New Element Medicine operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, NGM Biopharmaceuticals, Erasca and Revolution Medicines, among others.

  • Headquarter Zhenjiang, China
  • Founders Shi Dongfang
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Atom Therapeutics Co. Ltd.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $152.05 M (USD)

    in 5 rounds

  • Latest Funding Round
    $83 M (USD), Series D

    Oct 16, 2023

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of New Element Medicine

New Element Medicine offers a comprehensive portfolio of products and services, including ABP-671 and ABP-745. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Treats chronic gout and hyperuricemia through clinical trials.

Addresses acute gout with safety and efficacy in trials.

Funding Insights of New Element Medicine

New Element Medicine has successfully raised a total of $152.05M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $83 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Series D — $83.0M
  • First Round
  • Investors Count 13
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2023 Amount Series D - New Element Medicine Valuation Kaitai Capital Management
Jan, 2022 Amount Series C - New Element Medicine Valuation ShenZhen GTJA Investment Group
Jan, 2020 Amount Series B - New Element Medicine Valuation Kaitai Capital Management , Livzon Pharmaceutical
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in New Element Medicine

New Element Medicine has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Livzon Pharmaceutical, Kaitai Capital and Fortune Capital Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Kaitai Capital is engaged in innovation investment management services.
Founded Year Domain Location
-
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by New Element Medicine

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - New Element Medicine

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

New Element Medicine Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of New Element Medicine

New Element Medicine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, NGM Biopharmaceuticals, Erasca and Revolution Medicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
domain founded_year HQ Location
Biologics are developed for cardio-metabolic and liver diseases.
domain founded_year HQ Location
Small molecule therapeutics for cancer treatment are developed.
domain founded_year HQ Location
Cancer therapies are developed using selective pathway inhibitors.
domain founded_year HQ Location
MicroRNA-based therapeutics are developed for treating multiple diseases.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about New Element Medicine

When was New Element Medicine founded?

New Element Medicine was founded in 2012 and raised its 1st funding round 5 years after it was founded.

Where is New Element Medicine located?

New Element Medicine is headquartered in Zhenjiang, China. It is registered at Zhenjiang, Jiangsu, China.

Who is the current CEO of New Element Medicine?

Shi Dongfang is the current CEO of New Element Medicine. They have also founded this company.

Is New Element Medicine a funded company?

New Element Medicine is a funded company, having raised a total of $152.05M across 5 funding rounds to date. The company's 1st funding round was a Series B of $21.85M, raised on Jun 01, 2017.

What does New Element Medicine do?

Founded in 2012 and based in Zhenjiang, China, the company operates in the biotechnology sector. Focus is placed on developing pharmaceutical products for cancer and metabolic conditions. Pipeline includes URAT-1 targeting gout and hyperuricemia, as well as ABP-6061 and ABP-431 for non-alcoholic steatohepatitis, gastric cancer, colon cancer, and breast cancer. Operations center on research and drug development.

Who are the top competitors of New Element Medicine?

New Element Medicine's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

What products or services does New Element Medicine offer?

New Element Medicine offers ABP-671 and ABP-745.

Who are New Element Medicine's investors?

New Element Medicine has 13 investors. Key investors include Livzon Pharmaceutical, Kaitai Capital, Fortune Capital Partners, Huajin Securities, and NNFE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available